Profile data is unavailable for this security.
About the company
Straumann Holding AG is a Switzerland-based company active in the field of implant and restorative dentistry and oral tissue regeneration. In collaboration with clinics, research institutes and universities, the Group researches and develops implants, instruments, computer-aided design/manufacturing (CAD/CAM) prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann Holding AG also offers a range of services to the dental profession worldwide, including training and education, provided in collaboration with the International Team for Implantology (ITI). Its products and services are available in a number of countries through the Group’s headquarters and through a network of subsidiaries and technology partners located in Europe, North America, the Asia/Pacific region and in Latin America, including Dental Wings Inc based in Canada and Createch Medical SL based in Spain.
- Revenue in CHF (TTM)2.47bn
- Net income in CHF307.19m
- Incorporated2005
- Employees11.15k
- LocationStraumann Holding AGPeter Merian-Weg 12BASEL 4002SwitzerlandCHE
- Phone+41 619651111
- Fax+41 619651101
- Websitehttps://www.straumann.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Smith & Nephew plc | 4.97bn | 268.90m | 9.49bn | 18.00k | 35.23 | 2.07 | 11.16 | 1.91 | 0.274 | 0.274 | 5.07 | 4.67 | 0.5535 | 0.7128 | 4.30 | 239,873.70 | 2.99 | 4.10 | 3.62 | 4.99 | 69.04 | 71.27 | 5.41 | 8.02 | 1.11 | 5.48 | 0.4125 | 79.59 | 6.40 | 2.50 | 17.94 | -16.88 | 4.24 | 1.85 |
| BioMerieux SA | 3.57bn | 385.21m | 11.42bn | 14.65k | 29.75 | 3.14 | 17.28 | 3.20 | 3.46 | 3.46 | 32.04 | 32.80 | 0.7356 | 1.82 | 5.63 | 259,811.60 | 7.71 | 9.30 | 9.57 | 12.31 | 55.72 | 56.51 | 10.48 | 12.38 | 1.20 | 236.14 | 0.1258 | 17.76 | 2.39 | 8.70 | -20.95 | 6.87 | 8.36 | 19.42 |
| Sartorius AG | 3.11bn | 77.92m | 14.64bn | 13.76k | 154.08 | 4.84 | 30.02 | 4.70 | 1.22 | 1.22 | 48.66 | 38.73 | 0.3365 | 1.84 | 9.34 | 227,432.60 | 1.37 | 8.21 | 1.73 | 11.83 | 43.95 | 50.93 | 4.06 | 14.15 | 1.13 | 2.41 | 0.545 | 19.59 | -18.66 | 16.74 | -69.74 | 7.74 | 19.14 | 3.66 |
| Sartorius Stedim Biotech SA | 2.57bn | 158.47m | 16.92bn | 10.38k | 103.62 | 4.65 | 39.55 | 6.58 | 1.79 | 1.79 | 29.22 | 39.95 | 0.4145 | 1.75 | 8.84 | 257,644.00 | 2.61 | 11.87 | 3.04 | 15.12 | 41.82 | 50.96 | 6.31 | 17.44 | 1.03 | 2.95 | 0.4266 | 18.73 | -20.53 | 18.02 | -64.65 | 8.28 | 21.82 | 3.90 |
| Straumann Holding AG | 2.47bn | 307.19m | 17.68bn | 11.15k | 57.57 | 8.98 | 39.59 | 7.16 | 1.93 | 1.70 | 15.47 | 12.34 | 0.715 | 1.76 | 4.21 | 222,176.90 | 8.95 | 10.68 | 11.84 | 13.63 | 72.76 | 74.95 | 12.52 | 15.15 | 1.55 | 13.15 | 0.187 | 37.50 | 3.92 | 12.08 | -43.40 | -2.04 | 11.54 | 10.12 |
| Sonova Holding AG | 3.63bn | 601.00m | 19.07bn | 18.15k | 31.83 | 7.72 | 22.28 | 5.26 | 10.05 | 10.05 | 60.66 | 41.44 | 0.6394 | 2.35 | 6.82 | 199,818.20 | 10.75 | 10.87 | 13.45 | 13.88 | 72.28 | 71.97 | 16.80 | 17.77 | 1.07 | 31.44 | 0.4268 | 35.21 | -2.98 | 5.59 | -5.84 | 5.77 | 1.75 | 8.20 |
| Koninklijke Philips NV | 16.89bn | -439.25m | 21.59bn | 69.28k | -- | -- | 32.74 | 1.28 | -0.4847 | -0.335 | 19.14 | -- | -- | -- | -- | 258,972.70 | -- | 0.3678 | -- | 0.5013 | 42.18 | 43.84 | -2.59 | 0.6049 | -- | 5.35 | -- | -- | 1.92 | 0.0529 | 71.87 | -- | -5.24 | -- |
| Coloplast A/S | 3.39bn | 634.29m | 23.93bn | 16.25k | 40.10 | 11.39 | 30.06 | 7.05 | 22.61 | 22.61 | 121.01 | 79.62 | 0.5618 | 2.44 | 6.01 | 1,663,692.00 | 10.50 | 16.21 | 14.49 | 22.91 | 67.59 | 67.85 | 18.69 | 21.02 | 0.6637 | 8.49 | 0.5578 | 92.23 | 10.33 | 8.54 | 5.62 | 5.46 | 14.30 | 5.29 |
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 30 Sep 2024 | 5.19m | 3.25% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 3.68m | 2.31% |
| Comgest SAas of 31 Jul 2024 | 3.04m | 1.91% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 2.67m | 1.67% |
| BlackRock Investment Management (UK) Ltd.as of 07 Nov 2024 | 2.48m | 1.56% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Aug 2024 | 2.39m | 1.50% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 1.97m | 1.24% |
| Vontobel Asset Management AGas of 30 Sep 2024 | 1.55m | 0.98% |
| Morgan Stanley Investment Management Co.as of 31 Aug 2024 | 1.47m | 0.92% |
| Geode Capital Management LLCas of 07 Nov 2024 | 1.09m | 0.69% |
